Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2731 | NO gas Wiki | 0.50 |
| drug474 | BAY1237592 Wiki | 0.50 |
| drug3042 | PH-combination therapy Wiki | 0.50 |
Navigate: Correlations HPO
There are 4 clinical trials
In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure affecting the blood vessels in the lungs due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Pulmonary hypertension is characterized by the elevation of pressure in the pulmonary arteries (PAP) and of the pulmonary vascular resistance (PVR) leading to increased workload of the right chamber of the heart to eject blood against this elevated resistance. The goal of this study is to measure the safety and tolerability of the drug as well as the reduction of the PVR at different doses In Part A patients without specific treatment for PH (untreated patients) will be tested. In Part B patients stably pretreated with specific PH drugs will be studied in combination with the new inhaled drug
Description: PVR = 80* (PAP - PCWP) / CO (dyn·sec·cm-5) PAP = pulmonary arterial pressure PCWP = pulmonary capillary wedge pressure CO = cardiac output
Measure: Peak percent reduction in PVR (Pulmonary vascular resistance) from "baseline 2" for untreated patients Time: Up to 5 hours post inhalation of BAY1237592 compared to "baseline 2"Description: PVR = 80* (PAP - PCWP) / CO (dyn·sec·cm-5)
Measure: Peak percent reduction in PVR from "baseline" for pre-treated patients Time: Up to 5 hours post inhalation of BAY1237592 compared to "baseline"The virus infection Covid-19 fills our hospitals and intensive care departments in a very unique way and there is a lack of essential insight into the pathophysiology of the disease. As a result, very specific treatment options are missing. The US Medicines Agency (FDA) has in the last days given a general license for treatment with inhaled nitric oxide (iNO). Inhaled NO in Sweden (and Europe) is approved for the indication of pulmonary hypertension in adults. However, no one has yet described the occurrence of pulmonary hypertension, with or without right ventricular loading, in the Covid-19 patients who become so seriously ill that they need to be treated at an IVA ward. Knowledge of this is, of course, a prerequisite for determining the need for pulmonary artery catheterization (PA catheter, Swan-Ganz catheter) and also to better understand whether iNO treatment or other forms of lung selective vasodilation therapy may be of benefit to this patient group.
Description: To determine the prevalence of pulmonary hypertension and right ventricular load in patients with COVID-19 treated in intensive care unit evaluated by routine echocardiography.
Measure: Prevalence Time: Day 1With the appearance of the new SARS-COV2 virus, additional challenges are being imposed on the medical community after the resolution of acute COVID-19 illness, resulting in specific pathophysiologic mechanisms that while acutely damage the lung parenchyma might chronically impact the cardiopulmonary system. This study aims to investigate changes after mild COVID-19 illness in echocardiographic indices at rest and stress.
Description: Left atrium volume index
Measure: • LA volume index Time: 3 minutesDescription: Left ventricle telediastolic diameter
Measure: • LV telediastolic diameter Time: 3 minutesDescription: Left ventricle telesystolic diameter
Measure: • LV telesystolic diameter Time: 3 minutesDescription: Left ventricle posterior wall
Measure: • LV posterior wall Time: 3 minutesDescription: Right atrium area
Measure: • RA area Time: 3 minutesDescription: Right ventricle basal dimensión
Measure: • RV basal dimensión Time: 3 minutesDescription: Right ventricle cavity dimensión
Measure: • RV mid cavity dimension; Time: 3 minutesDescription: Right ventricle longitudinal dimension
Measure: • RV longitudinal dimension Time: 3 minutesDescription: Distal, right ventricle outflow tract dimension at the distal or pulmonic valve level
Measure: • Distal, RV outflow tract dimension at the distal or pulmonic valve level Time: 3 minutesDescription: Proximal right ventricle outflow tract dimension at the proximal subvalvular level
Measure: • Proximal RV outflow tract dimension at the proximal subvalvular level Time: 3 minutesDescription: • Tricuspid annular plane systolic excursion
Measure: • TAPSE Time: 3 minutesDescription: Right ventricle free Wall strain
Measure: • RV free Wall strain Time: 3 minutesDescription: Inferior cava vein PW Doppler
Measure: • Inferior cava vein PW Doppler Time: 3 minutesDescription: E wave mitral
Measure: • E wave mitral Time: 3 minutesDescription: A wave mitral
Measure: • A wave mitral Time: 3 minutesDescription: E wave /A wave mitral
Measure: • E wave /A wave mitral Time: 3 minutesDescription: E-wave at mitral annulus
Measure: • E-wave at mitral annulus Time: 3 minutesDescription: E-wave at mitral annulus / A-wave at the mitral annulus
Measure: • E-wave at mitral annulus / A-wave at the mitral annulus Time: 3 minutesDescription: E wave/ E-wave at the mitral annulus
Measure: • E wave/ E-wave at the mitral annulus Time: 3 minutesDescription: E tricuspid (E)
Measure: • E tricuspid (E) Time: 3 minutesDescription: A triuspid (A)
Measure: • A tricuspid (A) Time: 3 minutesDescription: E/A
Measure: • E/A Time: 3 minutesDescription: Systolic pulmonary artery pressure
Measure: • Systolic pulmonary artery pressure Time: 3 minutesDescription: E-wave at the tricuspid annulus
Measure: • E-wave at the tricuspid annulus Time: 3 minutesDescription: Mean pulmonary artery pressure
Measure: • Mean pulmonary artery pressure Time: 3 minutesDescription: Stroke volume
Measure: • Stroke volume Time: 3 minutesDescription: Cardiac output
Measure: • Cardiac output Time: 3 minutesCardiac dysfunction has been reported to be common in patients infected with COVID-19. The aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically ill patients infected with COVID-19.
Description: All cause death in patients with vs without cardiac dysfunction
Measure: Mortality Time: 30 daysDescription: Prevalence of left ventricular dysfunction
Measure: Left ventricular dysfunction Time: Within 72 hours from admissionDescription: Prevalence of right ventricular dysfunction
Measure: Right ventricular dysfunction Time: Within 72 hours from admissionDescription: Clinical variables associated with risk of having cardiac dysfunction
Measure: Risk-factors Time: Within 72 hours from admissionDescription: Levels of cardiac biomarkers in patients with vs without cardiac dysfunction
Measure: Cardiac biomarkers Time: Within 72 hours from admissionDescription: Prevalence of left ventricular dysfunction
Measure: Left ventricular dysfunction Time: During ICU-stayDescription: Prevalence of right ventricular dysfunction
Measure: Right ventricular dysfunction Time: During ICU-stayDescription: Clinical variables associated with risk of having cardiac dysfunction
Measure: Risk-factors Time: During ICU-stayDescription: Levels of cardiac biomarkers in patients with vs without cardiac dysfunction
Measure: Cardiac biomarkers Time: During ICU-stayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports